


CORRECTION

Correction: Marked variability in bioactivity between commercially available bovine colostrum for human use; implications for clinical trials

Raymond J. Playford, Meg Cattell, Tania Marchbank

In [Table 1](#), there are errors in the titles of the products tested under “COLOSTRUM”, the values under “Total stated protein (g/100 g)” and “Total IgG (g/100g)”, and the “Lot number” values. Please see the correct [Table 1](#) here.

Table shows source of colostrum samples and product data sheet information for total protein, total IgG, lot numbers and recommended storage conditions, NS = not stated. RT = (store at) room temperature. Storage advice was either present on data sheet or through direct contact with producer. NB list of products are described in random order and do not relate to the order of bioactivity.



OPEN ACCESS

Citation: Playford RJ, Cattell M, Marchbank T (2020) Correction: Marked variability in bioactivity between commercially available bovine colostrum for human use; implications for clinical trials. PLoS ONE 15(10): e0240392. <https://doi.org/10.1371/journal.pone.0240392>

Published: October 6, 2020

Copyright: © 2020 Playford et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Table 1. Commercial colostrum sample information provided by producer.

| COLOSTRUM | Total stated protein (g/100g) | Form | Source | Total IgG (g/100g) | Recommended storage | Lot number |
|--|-------------------------------|---------|-------------|--------------------|-------------------------------|--------------------|
| Neovite lactose reduced first milk | 70 | Powder | UK | 28 | Cool dry place | 1805082 |
| Neovite whole colostrum from Welsh farms | 55 | Powder | UK | 16.5 | Cool dry place | SA44-01 |
| Neovite cow's first milk | 55 | Powder | UK | 16.5 | Cool dry place | 1801007 |
| ColoDan whole colostrum | NS | Powder | Denmark | 13 | Cool dry place | B5032-017 |
| Bulkpowders colostrum | 63.3 | Powder | Germany | 30 | Cool dry place | NS |
| Biestmilch | 70 | Capsule | Hawaii | NS | Store for up to 3 year at RT | 171241 |
| Vitacost colostrum ultra | NS | Capsule | USA | 40 | Room Temp 15–30 °C | 3823400 |
| Douglas Laboratories colostrum | NS | Powder | New Zealand | NS | Cool dry place 15–25 °C | 50153284 |
| Immune Tree colostrum | 66.7 | Powder | USA | NS | Cool dry place | 9902/143 |
| Nutricost | NS | Capsule | USA | NS | NS (shipped at RT) | 18010466 |
| NOW colostrum powder | NS | Powder | USA | NS | Cool dry place | 3046338 |
| Nutrablast | NS | Capsule | USA | 7 | Cool dry place | 279331 |
| Sovereign Laboratories Colostrum-LD | 60 | Powder | USA | 25 | Cool dry place | 1802027 |
| Synertek Intact Balanced First colostrum | 66.7 | Powder | USA | NS | Cool dry place <25 °C | 657–30 |
| Renegade Pharmacist | 66.7 | Powder | USA | 22.11 | NS (shipped at RT) | 9902/221 |
| Sterling Technology colostrum 2070 | 70 | Powder | USA | 20 | NS (shipped at RT) | 0237418 |
| TBR labs peptide ignition colostrum | 66.7 | Powder | USA | >20 | Cool dry place | 03028219 |
| Sterling Technology colostrum 3070 | 70 | Powder | USA | 30 | NS (shipped at RT) | 2396–9 |
| Glanbia high fat WPC | 88 | Powder | USA | NS | NS (shipped at RT) | 0068701 |
| Pantheryx Standard colostrum 4515 | 45 | Powder | USA | 15 | Store at RT for up to 3 years | 1141–048203 4518Fi |

<https://doi.org/10.1371/journal.pone.0240392.t001>

Some of the symbols in the caption for Fig 4 are incorrect. Please see the complete, correct Fig 4 caption here. The publisher apologizes for the errors.




Fig 4. Change in colostrum biological and immunoactivity post calving using AGS cells. Colostrum was collected at first and second milking and daily for the following 3 days from 6 cows post calving. Samples were then analysed for pro-proliferative activity (AGS cells) using Alamar Blue and growth factor concentrations using commercial ELISA kits. A. Proliferative results comparing samples using 1 mg powder/ml. B. Proliferative results comparing samples standardised so that each well received 0.4 mg protein/ml. Results expressed as % response compared to effect caused by adding 1 µg/ml EGF (positive control, defined as 100%). SFM shows result of serum free medium alone. Results expressed as mean \pm SEM of 6 animals per time point, with each sample measured in quadruplicate. C. Change in total protein concentration in the dried colostrum samples over the four-day period. D. Growth factor immunoreactivity expressed as % of Day 0-1 sample (absolute values of day 0-1 given in main text); EGF (▲), TGFβ (▼), bovine haptoglobin (●), bovine betacellulin (■), IGF-1 (□) and IgG (○). Results expressed as mean \pm SEM of 6 animals per time point, with each sample measured in triplicate. For A-D, ** signifies $p < 0.01$ vs Day 0-1 value.

<https://doi.org/10.1371/journal.pone.0240392.g001>

Reference

1. Playford RJ, Cattell M, Marchbank T (2020) Marked variability in bioactivity between commercially available bovine colostrum for human use; implications for clinical trials. PLoS ONE 15(6): e0234719. <https://doi.org/10.1371/journal.pone.0234719> PMID: 32555629